帕罗西汀治疗帕金森病伴发抑郁障碍临床疗效与安全性分析  

Analysis of clinical efficacy and safety of paroxetine on treatment of Parkinson's disease with depressive disorder

作　　者：苗海锋[1] 马荣[1] 吴志强[1] 石铸[1] 李庆军[1] 刘玉华[1] 陈杭军[1] 

机构地区：[1]广东东莞市人民医院综合一科,东莞523000

出　　处：《中国实用神经疾病杂志》2014年第4期9-12,共4页Chinese Journal of Practical Nervous Diseases

基　　金：本课题受东莞市科技局资金资助;编号:20131051010091

摘　　要：目的探讨抗抑郁药帕罗西汀治疗帕金森病伴抑郁患者的疗效和不良反应。方法将50例帕金森病伴抑郁患者按随机数字表法分为治疗组和对照组,每组25例。2组均给予帕金森病的常规治疗,治疗组同时给予帕罗西汀片20mg,每日晨起顿服,对照组不使用任何抗抑郁药物,均持续治疗8周。在治疗前及治疗1、4、8周后分别进行统一帕金森病评定量表(The unified Parkinson‘s disease rating scale,UPDRS)评分、汉密尔顿抑郁量表(Hamilton Depression Scale,HAMD)评分,统计左旋多巴每日服用总量,使用不良反应量表(Treatment Emergent SymptomScale,TESS)评价其安全性。结果治疗8周后UPDRS评分2组比较差异有统计学意义(t=2.0678,P=0.0441),治疗4、8周后HAMD评分2组比较差异均有统计学意义(4周:t=2.1746,P=0.0346;8周:t=2.3080,P=0.0254),治疗8周后每日服用左旋多巴总量2组比较差异有统计学意义(t=2.0606,P=0.0448),治疗前和治疗8周后TESS评分2组比较差异无统计学意义(t=0.1101,P=0.9128)。结论帕罗西汀治疗帕金森病伴抑郁患者疗效确切,可减少左旋多巴用量,安全性良好。Objective To investigate tients with depressive disorder. Methods etficacy and adverse reaction o1 paroxetme on 50 cases of Parkinson＇s disease patients with me treatment oI yarKlnsons aiseabe pa- depression were randomly divided into treatment group and control group, 25 cases each group. Two groups of patients were given conventional treatment of Parkin- son＇s disease. The treatment group patients were received paroxetine tablets 20mg in the daily morning, and the control group patients weren＇t given any antidepressant drugs, treatment continued for 8 weeks. UPDRS scores, HAMD scores and the total daily doses of levodopa were measured respectively before treatment and at 1, 4, 8 weeks after the treatment. TESS scores were used to evaluate the safety. Results There was statistical significance between UPDRS scoher of the two groups after 8 weeks of treatment （t= 2. 0678 ,P^0. 0441）. The HAMD scores between two groups showed significant differences（after 4 weeks： t= 2. 1746,P= 0. 0346~after 8 weeks：t= 2. 3080, P= 0. 0254）. After 8 weeks of treatment, the total daily dose of levodopa showed significant difference between the two groups（t= 2. 0606, P=0. 0448）. TESS scores were not significant ly different be- tween the two groups. There was wo no significant difference between TESS scores of two groups before treatment and after 8weeks treatment （ t = O. 1101, P ： O. 9128 ） . Conclusion Paroxetine has a better therapeutic effect, less levodopa dosagesand good security in the treatment of Parkinson^s disease with depressive disorder.

关 键 词：帕金森病 左旋多巴 帕罗西汀 抑郁障碍 

分 类 号：R742.5[医药卫生—神经病学与精神病学]